1. Gilyarov, M.Yu., Novikova, N.A., Sarkisova, N.D., et al., Assessment of antithrombotic therapy of patients with atrial fibrillation, Kardiol. Serdechno-Sosudistaya Khir., 2011, no. 4, pp. 71–75.
2. Perepech, N.B. and Tregubov, A.V., Commitment of physicians to the use of antiplatelet agents in the prevention and treatment of cardiovascular diseases, Ratsion. Farmakoter. Kardiol., 2018, vol. 14, pp. 235–243.
3. Shevelev, V.I. and Kanorskii, S.G., Efficiency and safety of various methods of antithrombotic prevention of ischemic stroke in elderly patients with non-valve atrial fibrillation, Klin. Med., 2012, no. 90, pp. 61–63.
4. Apenteng, P.N., Gao, H., Hobbs, F.R., et al., Temporal trends in antithrombotic treatment of real-world UK patients with newly diagnosed atrial fibrillation: findings from the GARFIELD-AF registry, Br. Med. J. Open, 2018, vol. 8, p. e018905.
5. Camm, A.J., Kirchhof, P., Lip, G.Y., et al., Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC), Europace, 2010, vol. 12, pp. 1360–1420.